Extended Data Fig. 4: Effect of treatment on levels of soluble biomarkers in MIS-C.
a, Biomarker changes following systemic glucocorticoids in 12 MIS-C patients. Samples were drawn at a median of 0 days (IQR -1 to 0) prior to (left) and 5 days (IQR 4 to 7.5) after (right) treatment with glucocorticoids and IVIG (black lines) or glucocorticoids alone (red lines). Two patients (indicated by blue circles and lines) had received IVIG prior to blood sampling. Wilcoxon matched-pairs signed rank test with two-tailed P value was used for comparisons. *p < 0.05, **p < 0.01, ***p < 0.001. b, Comparison of soluble biomarker levels in MIS-C Early children (within 7 days since admission) who had not (untreated, n = 12) and in those who had (treated, n = 36) received glucocorticoids and/or IVIG prior to blood sampling. Results are compared to levels in MIS-C Late (>7 days since admission) patients (n = 60) and pediatric healthy controls (pHC, n = 53). Maxima of box plots represent median values, and bars represent interquartile range. Statistical analysis was performed by Kruskal-Wallis test with adjustment for multiple comparisons. P values are marked as follows: * <0.05, ** <0.01, *** <0.001, **** <0.0001. c, Random forest classification comparing MIS-C Early (n = 46) to pHC (n = 52), with treatment prior to blood sampling included among the variables. The sample cohort is the same as in Fig. 2e.
